Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Supernus Pharmaceuticals Inc    SUPN

SUPERNUS PHARMACEUTICALS INC (SUPN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/12/2018 06/13/2018 06/14/2018 06/15/2018 06/18/2018 Date
54(c) 54.05(c) 53.75(c) 54.95(c) 54.15(c) Last
486 036 466 740 567 836 908 113 522 566 Volume
-1.28% +0.09% -0.56% +2.23% -1.46% Change
More quotes
Financials (USD)
Sales 2018 402 M
EBIT 2018 136 M
Net income 2018 102 M
Finance 2018 189 M
Yield 2018 -
Sales 2019 489 M
EBIT 2019 191 M
Net income 2019 142 M
Finance 2019 282 M
Yield 2019 -
P/E ratio 2018 29,11
P/E ratio 2019 21,22
EV / Sales2018 6,60x
EV / Sales2019 5,25x
Capitalization 2 846 M
More Financials
Company
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases.Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.The firm also develops product candidates for the... 
Sector
Pharmaceuticals
Calendar
08/14Earnings Release
More about the company
Surperformance© ratings of Supernus Pharmaceuticals I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUPERNUS PHARMACEUTICALS I
06/13SUPERNUS PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holde..
AQ
06/01FARUQI & FARUQI, LLP : is Investigating Supernus Pharmaceuticals, Inc. (SUPN) on..
PR
05/31SUPERNUS PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (..
AQ
05/30SUPERNUS PHARMACEUTICALS : to Present at the 2018 Jefferies Healthcare Conferenc..
AQ
05/17SUPERNUS PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8..
AQ
05/11SUPERNUS PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financ..
AQ
05/10SUPERNUS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
AQ
05/09SUPERNUS PHARMACEUTICALS,INC. (NASDA : SUPN) Files An 8-K Results of Operations ..
AQ
05/09SUPERNUS : 1Q Earnings Snapshot
AQ
05/08SUPERNUS PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
AQ
More news
Sector news : Specialty & Advanced Pharmaceuticals
06/18How U.S. tax reform rewards companies that shift profit to tax havens
RE
06/18Evotec Shares Jump After It Secures Sanofi Agreement
DJ
06/18Indivior shares rise after U.S. court order blocks generic rival drug
RE
06/18INDIVIOR : Wins Legal Battle; Temporarily Blocks Launch of Generic Drug
DJ
06/18SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
06/17$SUPN "Chart Request" for A+ Setup, as far as I'm concerned however, i p..
7
06/09Supernus Pharmaceuticals $SUPN Downgraded by BidaskClub to Buy  
06/08Supernus Pharmaceuticals downgraded by BidaskClub to buy.  
06/08Supernus Pharmaceuticals Target of Unusually Large Options Trading $SUPN  
06/07Supernus Pharmaceuticals Target of Unusually High Options Trading $SUPN  
More tweets
Qtime:52
News from SeekingAlpha
06/13ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed 
06/05Supernus Keeps Delivering 
05/30Learning From The Best - How Joseph Edelman (Perceptive Advisors) Invests 
05/15Biotechs Emerge Unscathed And Ready To Go! 
05/09Supernus Pharmaceuticals' (SUPN) CEO, Jack Khattar on Q1 2018 Results - Earni.. 
Chart SUPERNUS PHARMACEUTICALS I
Duration : Period :
Supernus Pharmaceuticals I Technical Analysis Chart | SUPN | US8684591089 | 4-Traders
Technical analysis trends SUPERNUS PHARMACEUTICALS I
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 58,7 $
Spread / Average Target 6,8%
EPS Revisions
Managers
NameTitle
Jack A. Khattar President, CEO, Secretary & Director
Charles W. Newhall Chairman
Gregory S. Patrick Chief Financial Officer & Vice President
Padmanabh P. Bhatt Chief Scientific Officer & Senior Vice President
Stefan K. F. Schwabe Chief Medical Officer, EVP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SUPERNUS PHARMACEUTICALS INC37.89%2 846
ABBVIE2.96%158 006
MERCK KGAA-5.96%12 663
KYOWA HAKKO KIRIN CO LTD4.77%12 281
JAZZ PHARMACEUTICALS PLC32.27%10 685
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD67.36%9 912